Showing 131-140 of 155 results for "".
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug User Fee Act (…
- Ortho Dermatologics' DUOBRII Improves Psoriasis Symptoms As Early As Two Weekshttps://practicaldermatology.com/news/ortho-dermatologics-duobrii-improves-psoriasis-symptoms/2457811/DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy of Dermatology. DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion is an investigatio…
- Skin of Color Society Reports Banner Yearhttps://practicaldermatology.com/news/skin-of-color-society-reports-banner-year/2457824/Kudos to the Skin of Color Society (SOCS) for a banner year. At its recent annual business meeting held in conjunction with the 2018 Annual Meeting of the American Academy of Dermatology, SOCS President Seemal R. Desai, MD, President & Medical Director for Innovative Dermatology, PA, in Plano, Tex…
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Specifically, people wit…
- Psoriasis Severity Linked to Increased Risk of Deathhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-increased-risk-of-death/2458074/The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania. In fact, patients with psoriasis on 10 percent or more of their body are at almost double the risk…
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for th…
- Face-Aging App May Encourage Sun-Safe Behaviorhttps://practicaldermatology.com/news/face-aging-app-may-encourage-sun-safe-behavior/2458460/Appealing to their vanity may be the best way to encourage young women to practice sun-safe behaviors, a new study shows. The new research, published in Cogent Psychology, studied the differences between text-based and visual messages and examined whether warning about future appearance has an im…
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approval and commercialization of RT002 injectable, a novel n…
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psor…
- Laser Combination Therapy Promising for Cutaneous Leishmaniasishttps://practicaldermatology.com/news/laser-combination-therapy-promising-for-cutaneous-leishmaniasis/2458769/Combination therapy using ablative fractional laser resurfacing, in combination with laser-assisted delivery of topical paromomycin appears to be effective for treatment of leishmaniasis, according to a pilot study published in the December 2015 issue of Lasers in Surgery and Medicine (LSM). The re…